Optimizing Low Threshold TelePrEP Care in Syringe Service Programs for People who Inject Drugs in Appalachia

Grants and Contracts Details

Description

ABSTRACT Kentucky (KY) is a high priority Ending the HIV Epidemic (EHE) jurisdiction due to heavy rural HIV burden and exceptionally high rates of new HIV diagnoses driven by injection drug use (IDU): 32% of newly HIV-diagnosed women in KY have IDU as a transmission factor, as do 15% of men, compared to 16% and 5%, respectively, across the US. Despite ongoing need for robust HIV prevention and the strong evidence for Pre-Exposure Prophylaxis (PrEP), uptake remains severely limited among people who inject drugs (PWID). PWID are notably impacted by structural challenges that impede entry and retention in PrEP care, including poverty and unstable housing, violence, social isolation, and stigma; in rural and remote areas, including Appalachia, limited healthcare access and a dearth of PrEP providers further constrain access to PrEP along geographic boundaries. An interim assessment of EHE progress notes that PrEP coverage remains well below threshold to reach established EHE targets, and sets out broad policy recommendations to enhance PrEP access by engaging people where they are. For PWID in particular, there is broad scientific consensus that PrEP efforts be intensified and intentional in supporting low threshold PrEP access. The proposed study will leverage KY’s robust harm reduction infrastructure to develop, integrate and test a low threshold peer- facilitated TelePrEP intervention for Appalachian PWID in syringe service programs (SSPs) that operate within “PrEP deserts,” filling a critical need to implement innovative approaches that mitigate geographic disparities in PrEP access. The PI’s ongoing research and existing partnerships with local health department SSPs in Appalachian KY have demonstrated that PWID have low PrEP awareness and social determinant barriers to PrEP uptake, yet interest in PrEP is high, at 73%. Although PWID in KY report stigmatizing experiences from healthcare providers in traditional care sites (stigma paper), preliminary data indicate high acceptability to participate in PrEP education and point of care PrEP testing within Appalachian SSPs. Building on this existing work and strong partnerships with clinical and community providers, we will conduct a pilot randomized trial to examine effectiveness on PrEP initiation (measured by dispensed PrEP prescription and biomarker confirmation of use) and retention in PrEP care 6-months post-baseline (measured by self-report and biomarker confirmation) as well as implementation outcomes guided by the Implementation Outcomes Framework. The Specific Aims are to: 1) Collaborate with the CCHD and KRDHD harm reduction communities to develop the optimal content, delivery structure, and implementation strategies for the peer- facilitated TelePrEP intervention in SSPs and rapidly manualize the novel low threshold protocol; 2) Conduct a pilot randomized trial to evaluate the preliminary efficacy of: a) peer-facilitated, integrated TelePrEP compared with b) peer-delivered PrEP navigation and referral, on PrEP initiation and persistence among Appalachian PWID; 3) Examine feasibility, acceptability, appropriateness, and fidelity implementation outcomes of the two intervention comparators among PWID participants and partner harm reduction staff using a mixed methods approach. The proposed study will establish preliminary evidence and proof-of-concept for an integrated low-threshold TelePrEP intervention for Appalachian PWID, which is designed to extend the reach of PrEP to areas with known geographic access disparities. Innovative interventions to increase PrEP initiation and persistence by PWID in non-traditional care settings fill a critical need for studies to improve the PrEP care cascade among PWID. Robust translation plans will ensure that study findings inform best practice service models through dissemination of findings to scientific and practitioner audiences and community-based clinical care organizations.
StatusActive
Effective start/end date5/1/244/30/25

Funding

  • National Institute on Drug Abuse: $194,380.00

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.